Cardiovascular Benefits
Cross-source consensus on Cardiovascular Benefits from 1 sources and 4 claims.
1 sources · 4 claims
Benefits
Evidence quality
Highlighted claims
- In the SELECT trial, semaglutide lowered MACE risk in adults with established ASCVD and BMI ≥27 who did not have diabetes. — GLP-1 Medications: A Comprehensive Clinical Guide
- A meta-analysis found that GLP-1 receptor agonists reduced major adverse cardiovascular events by 14% in patients with diabetes. — GLP-1 Medications: A Comprehensive Clinical Guide
- GLP-1 receptor agonists reduced hospitalizations for heart failure by 11% in patients with diabetes. — GLP-1 Medications: A Comprehensive Clinical Guide
- Whether the cardiovascular benefits of GLP-1 medications are drug-direct effects or mediated by weight loss remains under active investigation. — GLP-1 Medications: A Comprehensive Clinical Guide